AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6198057 — intervention group
Group type: COMPARATOR
Intervention: Kwellada shampoo (1% lindane)
Number of subjects: 62
Study 29133220 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Diet
Number of subjects: 149
Study 29133220 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 149
Study 29133220 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 149
Study 29133220 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 149
Study 26843538 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial physiotherapist examination and follow-up clinical evaluation
Number of subjects: 90
Study 26843538 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up clinical evaluation after 7 days
Number of subjects: 90
Study 26843538 — intervention group
Group type: COMPARATOR
Intervention: MRI evaluation
Number of subjects: 90
Study 25668306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 1530
Study 25668306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 1530
Study 25668306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1530
Study 25668306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 1530
Study 23792399 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit root canal treatment
Number of subjects: 287
Study 23792399 — intervention group
Group type: COMPARATOR
Intervention: Two-visit root canal treatment
Number of subjects: 287
Study 20862744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucinous adenocarcinoma
Number of subjects: 4000
Study 20862744 — intervention group
Group type: COMPARATOR
Intervention: Serous carcinoma
Number of subjects: 4000
Study 18368947 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol (20 µg, inhaled three times a day)
Number of subjects: 20
Study 18368947 — intervention group
Group type: COMPARATOR
Intervention: Oxitropium bromide (200 µg, inhaled three times a day)
Number of subjects: 20
Study 17165499 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Chinese medicine
Number of subjects: 58
Study 17165499 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine
Number of subjects: 58
Study 15375474 — intervention group
Group type: EXPERIMENTAL
Intervention: Open commissurotomy (GC)
Number of subjects: 81
Study 15375474 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon valvuloplasty (GV)
Number of subjects: 81
Study 15375474 — intervention group
Group type: COMPARATOR
Intervention: Both groups (GC and GV)
Number of subjects: 81
Study 11100349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (TPN) when total bilirubin > 5 mg% (Group A2)
Number of subjects: 65
Study 11100349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (TPN) when total bilirubin > 10 mg% (Group B2)
Number of subjects: 65
Study 11100349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (TPN) when total bilirubin > 20 mg% (Group C2)
Number of subjects: 65
Study 11100349 — intervention group
Group type: COMPARATOR
Intervention: Non-cyclic total parenteral nutrition (TPN)
Number of subjects: 65
Study 9745829 — intervention group
Group type: EXPERIMENTAL
Intervention: Belgian OAG patients
Number of subjects: 51
Study 9745829 — intervention group
Group type: EXPERIMENTAL
Intervention: Congolese OAG patients
Number of subjects: 51
Study 9745829 — intervention group
Group type: COMPARATOR
Intervention: Belgian normal eyes
Number of subjects: 51
Study 9745829 — intervention group
Group type: EXPERIMENTAL
Intervention: Congolese specimens
Number of subjects: 51
Study 9745829 — intervention group
Group type: COMPARATOR
Intervention: Belgian specimens
Number of subjects: 51
Study 8383933 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium (0.05 mg/kg)
Number of subjects: 30
Study 8383933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.14 mg/kg)
Number of subjects: 30
Study 8383933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium (0.10 mg/kg)
Number of subjects: 30
Study 8383933 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium, Pipecuronium, Doxacurium
Number of subjects: 30
Study 3724575 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional training programme in ambulatory diabetes care
Number of subjects: 0
Study 3724575 — intervention group
Group type: COMPARATOR
Intervention: Teaching role assigned to nurses
Number of subjects: 0
Study 3724575 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning from a nurse
Number of subjects: 0
Study 31615775 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of testosterone cream daily for 10 weeks
Number of subjects: 48
Study 31615775 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 48
Study 28984843 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly family psychosocial intervention
Number of subjects: 391
Study 28984843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 391
Study 26690886 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 256
Study 26690886 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib without BCAA supplementation
Number of subjects: 256
Study 25402400 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement Planning (CEP)
Number of subjects: 1018
Study 25402400 — intervention group
Group type: COMPARATOR
Intervention: Technical Assistance to Individual Programs (RS)
Number of subjects: 1018
Study 22648466 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg · kg‐1)
Number of subjects: 18
Study 22648466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20921123 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (initial oral loading followed by 1998 mg daily)
Number of subjects: 33
Study 20921123 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 33
Study 20921123 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 33
Study 19419923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with carboplatin/paclitaxel
Number of subjects: 0
Study 19419923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with cisplatin/gemcitabine
Number of subjects: 0
Study 15976996 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure (MIP) post-exercise
Number of subjects: 34
Study 15976996 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip (HG) strength post-exercise
Number of subjects: 34
Study 11406895 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 11
Study 9372653 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (975 mg)
Number of subjects: 0
Study 9372653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9372653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.12 ppm)
Number of subjects: 0
Study 9372653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.4 ppm)
Number of subjects: 0
Study 8447444 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP
Number of subjects: 6
Study 8447444 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP
Number of subjects: 6
Study 3501540 — intervention group
Group type: EXPERIMENTAL
Intervention: FUra plus leucovorin (200 mg/m2 daily for 5 days)
Number of subjects: 78
Study 3501540 — intervention group
Group type: EXPERIMENTAL
Intervention: FUra plus leucovorin (20 mg/m2 daily for 5 days)
Number of subjects: 78
Study 3501540 — intervention group
Group type: COMPARATOR
Intervention: FUra (control)
Number of subjects: 78
Study 30365408 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% topical ketoprofen gel
Number of subjects: 0
Study 30365408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29720874 — intervention group
Group type: EXPERIMENTAL
Intervention: Life coaching intervention
Number of subjects: 14
Study 28116440 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL combined with SP
Number of subjects: 104
Study 28116440 — intervention group
Group type: COMPARATOR
Intervention: LBL
Number of subjects: 104
Study 22981277 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine myocardial perfusion imaging (MPI) with heart rate response (HRR) measurement
Number of subjects: 518
Study 22981277 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR <20%
Number of subjects: 518
Study 22981277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/large abnormal MPI
Number of subjects: 518
Study 22981277 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR ≥ 40%
Number of subjects: 518
Study 22981277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both abnormal MPI and HRR
Number of subjects: 518
Study 21562038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate (IV MTX) during interim maintenance phases
Number of subjects: 2078
Study 21562038 — intervention group
Group type: COMPARATOR
Intervention: Oral methotrexate (PO MTX) during interim maintenance phases
Number of subjects: 2078
Study 21562038 — intervention group
Group type: EXPERIMENTAL
Intervention: Single delayed intensification (DI) phase
Number of subjects: 2078
Study 21562038 — intervention group
Group type: COMPARATOR
Intervention: Double delayed intensification (DI) phase
Number of subjects: 2078
Study 19433681 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified high-dose induction phase (arm A): 4 weeks of 10 MU/m² IFN-alpha-2b IV for 2 weeks and 10 MU/m² IFN-alpha-2b SC for 2 weeks followed by 23 months of low-dose IFN-alpha-2b 3 MU SC three times a week
Number of subjects: 674
Study 19433681 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IFN-alpha-2b only (arm B): 3 MU three times a week for 24 months
Number of subjects: 674
Study 16857846 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of Se per day
Number of subjects: 43
Study 16857846 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of Se per day
Number of subjects: 43
Study 16857846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 12603782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink (TFD)
Number of subjects: 5
Study 12603782 — intervention group
Group type: COMPARATOR
Intervention: Control drink (TFD plus tryptophan)
Number of subjects: 5
Study 10990220 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg tablet once daily for 13 days)
Number of subjects: 20
Study 10990220 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone (10 mm/week)
Number of subjects: 20
Study 9266782 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol infusion
Number of subjects: 471
Study 9266782 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 471
Study 8336195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and mitomycin (CM)
Number of subjects: 70
Study 8336195 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and doxorubicin (CD)
Number of subjects: 70
Study 3297596 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 57
Study 3297596 — intervention group
Group type: COMPARATOR
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 57
Study 29065734 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G FNA needle
Number of subjects: 60
Study 29065734 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G FNB needle
Number of subjects: 60
Study 27596004 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone counseling (n = 24)
Number of subjects: 54
Study 27596004 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 54
Study 23643690 — intervention group
Group type: EXPERIMENTAL
Intervention: GDT performed 5min after stress onset
Number of subjects: 3
Study 23643690 — intervention group
Group type: EXPERIMENTAL
Intervention: GDT performed 18min after stress onset
Number of subjects: 3
Study 23643690 — intervention group
Group type: EXPERIMENTAL
Intervention: GDT performed 28min after stress onset
Number of subjects: 3
Study 23643690 — intervention group
Group type: COMPARATOR
Intervention: Control group GDT performance
Number of subjects: 3
Study 20883237 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 138
Study 20883237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 18383415 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 0
Study 18383415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22111436 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction II (LTS II)
Number of subjects: 54
Study 22111436 — intervention group
Group type: COMPARATOR
Intervention: Proseal Laryngeal Mask Airway (PLMA)
Number of subjects: 54
Study 16148284 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg once daily for seven days)
Number of subjects: 1565
Study 16148284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1565
Study 11792952 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate
Number of subjects: 0
Study 11792952 — intervention group
Group type: COMPARATOR
Intervention: Suture
Number of subjects: 0
Study 9631752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administered every 4 weeks, with NSAIDs initially maintained.
Number of subjects: 7
Study 7868668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tru-Trax system using bovine mucus
Number of subjects: 133
Study 7868668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tru-Trax system using human mucus
Number of subjects: 133
Study 7868668 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-coital tests using human mucus in the Tru-Trax system
Number of subjects: 133
Study 7868668 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall penetration into either human or bovine mucus
Number of subjects: 133
Study 2969002 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prednisone (100 micrograms/kg)
Number of subjects: 8
Study 2969002 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate day prednisone (200 micrograms/kg)
Number of subjects: 8
Study 2969002 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily and alternate day prednisone treatments
Number of subjects: 8
Study 30443729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal MAP (65-75 mmHg)
Number of subjects: 120
Study 30443729 — intervention group
Group type: COMPARATOR
Intervention: High-normal MAP (80-100 mmHg)
Number of subjects: 120
Study 28915067 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 211
Study 28915067 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 211
Study 25740262 — intervention group
Group type: COMPARATOR
Intervention: Daclatasvir (DCV) single oral doses of 1/10/50/100/200 mg
Number of subjects: 129
Study 25740262 — intervention group
Group type: COMPARATOR
Intervention: Asunaprevir (ASV) single oral doses of 200/400/600/900/1200 mg
Number of subjects: 129
Study 25740262 — intervention group
Group type: COMPARATOR
Intervention: Daclatasvir (DCV) multiple oral doses of 1/10/100 mg once-daily for 14 days
Number of subjects: 129
Study 25740262 — intervention group
Group type: COMPARATOR
Intervention: Asunaprevir (ASV) multiple oral doses of 200/400/600 mg every 12 hours for 14 days
Number of subjects: 129
Study 23739921 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic hand exercises
Number of subjects: 52
Study 23739921 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric hand exercises
Number of subjects: 52
Study 20625270 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 97
Study 20625270 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 97
Study 18280668 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted, counselor-delivered smoking cessation program
Number of subjects: 426
Study 18280668 — intervention group
Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 426
Study 16504492 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 5 days
Number of subjects: 563
Study 16504492 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily for 7 days
Number of subjects: 563
Study 16504492 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 563
Study 16504492 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 563
Study 16504492 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Levofloxacin
Number of subjects: 563
Study 12589011 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUTT) with haemodynamic instability score (HIS)
Number of subjects: 40
Study 10857822 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium laser phacoemulsification
Number of subjects: 34
Study 8871412 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactivating AAI strategies
Number of subjects: 61
Study 8871412 — intervention group
Group type: EXPERIMENTAL
Intervention: Deactivating AAI strategies
Number of subjects: 61
Study 1641600 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg b.i.d.
Number of subjects: 86
Study 1641600 — intervention group
Group type: COMPARATOR
Intervention: erythromycin stearate 500 mg b.i.d.
Number of subjects: 86
Study 6672890 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-mask during sleep
Number of subjects: 20
Study 6672890 — intervention group
Group type: COMPARATOR
Intervention: No face-mask during sleep
Number of subjects: 20
Study 28138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with CONSORT criteria
Number of subjects: 6
Study 28138753 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct implementation of CONSORT criteria
Number of subjects: 6
Study 27776536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index breakfast (dark chocolate, walnuts, yogurt, and an apple; glycaemic index of 29.4; energy contribution of 1489 kJ)
Number of subjects: 3
Study 27776536 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index breakfast (bread, grape juice, and strawberry jam; glycaemic index of 64.0; energy contribution of 1318 kJ)
Number of subjects: 3
Study 27776536 — intervention group
Group type: COMPARATOR
Intervention: Control condition (water)
Number of subjects: 3
Study 23525574 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus ciprofloxacin
Number of subjects: 76
Study 23525574 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab plus placebo
Number of subjects: 76
Study 23678504 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions (BIs) performed by occupational doctors, 10-minute average duration, motivational approach
Number of subjects: 787
Study 23678504 — intervention group
Group type: COMPARATOR
Intervention: Control group received information booklets from doctors' assistants
Number of subjects: 787
Study 20710083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation (specific dosage and duration not provided)
Number of subjects: 0
Study 20710083 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization of adverse event terminology and reporting
Number of subjects: 0
Study 17981886 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological scoring by nephropathologists
Number of subjects: 87
Study 17981886 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity index for LN
Number of subjects: 87
Study 17981886 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronicity index for LN
Number of subjects: 87
Study 17981886 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO1995 and ISN/RPS2003 classification systems for LN
Number of subjects: 87
Study 17981886 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients classified as IV-S
Number of subjects: 87
Study 17981886 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between IV-S and IV-G
Number of subjects: 87
Study 17130263 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg) for 16 weeks
Number of subjects: 52
Study 17130263 — intervention group
Group type: COMPARATOR
Intervention: Healthy control individuals (25 subjects)
Number of subjects: 52
Study 15200727 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 42
Study 15200727 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 11552355 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie-concept, mobilisation therapies, traction
Number of subjects: 0
Study 11552355 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physiotherapies (training of local strength endurance of back and abdominal muscles)
Number of subjects: 0
Study 11552355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain reducing physical therapies (cold or electrotherapy)
Number of subjects: 0
Study 11552355 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs, analgesics, muscle relaxants
Number of subjects: 0
Study 9382981 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α therapy
Number of subjects: 37
Study 8037993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (40 mg isosorbide dinitrate twice daily)
Number of subjects: 54
Study 8037993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2967448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms + Ipratropium 80 micrograms
Number of subjects: 10
Study 2967448 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms
Number of subjects: 10
Study 31281988 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-4474 (100 mg, orally, twice daily for 28 days)
Number of subjects: 110
Study 31281988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 31281988 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-4474
Number of subjects: 110
Study 31281988 — intervention group
Group type: COMPARATOR
Intervention: ONO-4474 vs Placebo
Number of subjects: 110
Study 29165623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 546
Study 29165623 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 546